HBIO: Harvard Bioscience, Inc. Company Buyout Price

The market trend for Harvard Bioscience (HBIO) shown on this price chart reflects an enterprise value of 75.59. The business's moat relies on the ownership of unique patents and strict FDA oversight, which limits the entry of new players. Harvard Bioscience provides core equipment for global laboratories, facilitating cell research. The current strategic vector is focused on releasing high-margin precision dosing and analysis systems.

HBIO (Harvard Bioscience, Inc.) Total Company Value history from 11/23/2025 to 10/27/2026

HBIO (Harvard Bioscience): analytical breakdowns and indicator data

- price and consensus price forecast:

Price Chart Harvard Bioscience Inc.|HBIO - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Harvard Bioscience|HBIO - Total Company Value

- book capitalization data:

Net Asset Value per Share Harvard Bioscience|HBIO - Company Book Value|Market Cap to Net Assets Ratio harvardbioscience.com|HBIO - Company Total Assets

- debt and liquidity data:

Debt to Capital Harvard Bioscience|HBIO - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio harvardbioscience.com|HBIO - Company Aggregate Debts|Debts to Net Assets Harvard Bioscience

General company analysis:HBIO (Harvard Bioscience Inc.)

Original product of Harvard Bioscience Inc.

Enterprise value determines the total cost of a full business buyout, accounting for all liabilities. This metric combines market capitalization and net debt, excluding available cash. Analyzing the full fundamental value of the company allows for an assessment of the asset's real price. The trend in the full fundamental value of Harvard Bioscience (HBIO) reflects the investment attractiveness of its robotic systems. High values for this metric confirm the market value of its automated biomonitoring equipment.

Competitor analysis for Harvard Bioscience